209
Participants
Start Date
August 7, 2012
Primary Completion Date
August 11, 2015
Study Completion Date
August 2, 2016
MORAb-004
IV, Days 1 and 8 of every cycle until disease progression
Gemcitabine
IV, Days 1 and 8 of each cycle until disease progression
Docetaxel
IV, Day 8 of every cycle until disease progression
Gemcitabine
IV, Days 1 and 8 of each cycle until disease progression
Docetaxel
IV, Day 8 of every cycle until disease progression
Placebo
Royal North Shore Hospital, St Leonards
Dana-Farber Cancer Institute, Boston
Canberra Hospital, Garran
UZ Leuven Medical Oncology, Leuven
Princess Alexandra Hospital, Woolloongabba
Ashford Cancer Centre Research, Kurralta Park
Sir Charles Gairdner Hospital, Perth
Mount Sinai Medical Center, New York
Fox Chase Cancer Center, Philadelphia
Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
The University of North Carolina at Chapel Hill, Chapel Hill
Mayo Clinic Jacksonville, Jacksonville
University of Miami, Miami
Moffitt Cancer Center, Tampa
Istituto Ortopedico Rizzoli, Bologna
University of Michigan Health System, Ann Arbor
Siouxland Hematology-Oncology, Sioux City
Mayo Clinic - Rochester, Rochester
Northwestern Memorial Hospital, Chicago
Washington University, St Louis
University of Claude Bernard, Villeurbanne
MD Anderson Cancer Center, Houston
Huntsman Cancer Institute at the University of Utah, Salt Lake City
Sarcoma Oncology Center, Santa Monica
UCLA, Santa Monica
Institut Gustave Roussy, Villejuif
Oregon Health and Science University, Portland
Seattle Care Alliance, Seattle
Leiden University Medical Center, Leiden
Lead Sponsor
Morphotek
INDUSTRY